Herpes zoster
☆ AI Dermatology — Free Service
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Herpes zoster ròro lórí ọ̀run àti ejika.
relevance score : -100.0%
ReferencesShingles, ti o fa nipasẹ isọdọtun ọlọjẹ varicella‑zoster ti o ni iduro fun adie, kan awọn miliọnu eniyan lododun ni Amẹrika, pẹlu eewu iku ti 30 %. Awọn ẹni tí ó ní eto ajẹsara aláìlágbára jẹ́ aláìlera sí i nígbà tí shingles bá ń dagba, níbẹ̀ tí aami aisan máa ń bẹ̀rẹ̀ pẹ̀lú àìlera, orififo, àti ibà kékeré, lẹ́yìn náà tí a bá rí àìlera awọ̀ ara tó ń pọ̀ sí i ní ọjọ́ díẹ̀ ṣáájú hihan sísú kan. Sísú yìí, tí ó máa ń hàn ní àgbègbè kan pàtó lórí ara, ń gùnà láti àwọ̀n ròró tó hàn gbangba sí àwọn egbò erunrun fún ọ̀sẹ̀ kan sí ọjọ́ mẹ́wàá. Itọju kíákíá pẹ̀lú àwọn oogun antiviral (acyclovir, valacyclovir, tàbí famciclovir) ní àkókò tó kéré jù 72 wákàtí láti ìbẹ̀rẹ̀ sísú jẹ́ pàtàkì. Postherpetic Neuralgia, ìṣòro tó wọ́pọ̀ tí ó ń ṣàfihàn irora tó ń pẹ́ ní àgbègbè tí ó kan, máa ń kan ọ̀kan nínú àwọn aláìsàn márùn‑ún, ó sì nílò ìṣàkóso pẹ̀lú àwọn oogun bí gabapentin, pregabalin, tàbí àwọn antidepressants, pẹ̀lú àwọn aṣọ̀ọ́rọ̀ àgbègbè bí lidocaine tàbí capsaicin. Ajesara lòdì sí ọlọjẹ varicella‑zoster ni a ṣe iṣeduro fún àwọn agbalagba tó wà láàrin ọdún 50 àti ju bẹ́ẹ̀ lọ kí wọ́n lè dín eewu shingles ku.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Herpes zoster maa n waye nigbagbogbo laarin awọn eniyan ti o ti ju ọdun 50 lọ, awọn agbalagba, awọn ti o ni eto ajẹsara alailagbara, àti awọn ti o nlo awọn oogun ajẹsara. O jẹ nitori isọdọtun ọlọjẹ varicella‑zoster, ọlọjẹ kanna ti o fa adie. Awọn aami aisan bii iba, irora, àti nyún maa n ṣaju hihan sisu iwa naa. Ipalara ti o wọpọ julọ ni neuralgia post‑herpetic, eyi ti o jẹ irora nẹ́rọ̀ ara tí ó ń bá a lọ lẹ́yìn tí àfarawọ̀ náà ti rọ̀. Awọn ifosiwewe ewu àti awọn ilolu tí ó ní í ṣe pẹ̀lú zoster Herpes yàtọ̀ sí ọjọ‑ori, ilera ajẹsara, àti àkókò ibẹrẹ ìtòjú. Ajẹsara fún àwọn ẹni‑kọ̀ọ̀kan tí ọjọ‑ori wọn jẹ́ 60 ọdún tàbí ju bẹ́ẹ̀ lọ ti hàn pé ó dínà ìṣẹ̀lẹ̀ zoster herpes àti neuralgia post‑herpetic. Bí a ṣe bẹ̀rẹ̀ lílo àwọn oogun antiviral àti àwọn olùtúra irora ní àárín wákàtí 72 lẹ́yìn ìbẹ̀rẹ̀ sisu, ó lè dínà bí a ṣe ń ní àìlera àti àwọn ilolu tí ó ní í ṣe pẹ̀lú zoster herpes àti neuralgia post‑herpetic.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Awọn idanwo ile-iwosan ṣaaju ifọwọsi tọka pé ajesara zoster laaye n ṣiṣẹ ní àárín 50 sí 70 %, nígbà tí ajesara atunmọ ṣe dára jùlọ, pẹ̀lú àgbègbè 90 sí 97 %. Nínú àwọn ìjìnlẹ̀ gidi-àyé, wọn ṣe àtìlẹ́yìn fún àwọn àbájáde yìí, tí ń fìhàn pé ajesara laaye jẹ́ tó 46 % ní ìmunadoko, nígbà tí ti atunmọ wà ní àárín 85 %.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
Chickenpox, ti a tún pè ní varicella, jẹ́ abajade àkóràn àkọ́kọ́ tí ó ń ṣẹlẹ̀ pẹ̀lú ọlọ́jẹ̀ náà, tí ó máa ń hù nígbà ìgbà ọmọde tàbí ọdọ. Lẹ́yìn tí àrùn náà bá ń bọ́, ọlọ́jẹ̀ náà lè wà ní àìṣiṣẹ́ (latent) nínú àwọn sẹ́lì nafu ènìyàn fún ọdún púpọ̀ tàbí ọ̀pọ̀ ọdún, lẹ́yìn náà ó lè tún ṣiṣẹ́. Herpes zoster máa ń ṣẹlẹ̀ nígbà tí ọlọ́jẹ̀ varicella tó wà ní àìṣiṣẹ́ bá tún ṣiṣẹ́. Lẹ́yìn náà, ọlọ́jẹ̀ náà ń rìn àjò pẹ̀lú àwọn ara iṣan sí àwọn ipò nafu nínú awọ̀ ara, tí ń yọ̀rí sí ìfarahan àwọn roro. Nígbà tí herpes zoster bá ń ṣẹlẹ̀, àfihàn sí ọlọ́jẹ̀ varicella tó wà nínú roro herpes zoster lè fa àrùn náà ní ẹni tí kò tíì ní àrùn yìí.
Àwọn àǹfààní ewu fún àtúnfarapa ọlọ́jẹ̀ náà ní ọjọ́-ògbó, eto ajẹsara tí kò dára, àti bí ẹni bá ní àrùn àdíẹ̀ ṣáájú ọjọ́-ọdún 18. Olùkó Varicella‑zoster kò dà bí ọlọ́jẹ̀ Herpes simplex, bó tilẹ̀ jẹ́ pé méjèèjì wà nínú ẹbí kan náà ti àwọn ọlọ́jẹ̀ herpes.
Àwọn àjẹ́ṣà herpes zoster dínkù ewu herpes zoster ní 50 % sí 90 %. Ó tún dínkù oṣùwànsí neuralgia postherpetic, àti, bí herpes zoster bá ṣẹlẹ̀, ìbànújẹ rẹ̀. Bí herpes zoster bá ń dagba, àwọn ọ̀gùn antiviral bíi aciclovir lè dínkù ìbànújẹ àti àkókò arun náà tí a bá bẹ̀rẹ̀ ní àkókò tó wà láàrin wákàtí 72 lẹ́yìn tí a ti rí aami.
○ Itọju
Ti aami bá ń tan kaakiri, wá dókítà rẹ lẹ́sẹ̀kẹsẹ fún itọju antiviral.
Àpọ̀ọ̀mọdé àwọn ọ̀gùn antiviral àti àwọn ọ̀gùn neuralgia ni a nílò. O yẹ kí o sinmi, kí o sì yá ara rẹ kúrò nínú mímu ọtí.
#Acyclovir
#Fancyclovir
#Valacyclovir
#Gabapentin
#Pregabalin